Aurobindo closes up 2% on approvals for Rizatriptan

Healthcare firm Aurobindo Pharma rose 2.11 percent to close at Rs 193.30 on the Bombay Stock Exchange on Tuesday as the company has received final approval from the US Food & Drug Administration to manufacture and market Rizatriptan Benzoate Tablets.
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead master your money SME Special
moneycontrol.com

Home » News » Business

Jan 01, 2013, 05.32 PM | Source: Moneycontrol.com

Aurobindo closes up 2% on approvals for Rizatriptan

Healthcare firm Aurobindo Pharma rose 2.11 percent to close at Rs 193.30 on the Bombay Stock Exchange on Tuesday as the company has received final approval from the US Food & Drug Administration to manufacture and market Rizatriptan Benzoate Tablets.

Like this story, share it with millions of investors on M3

Aurobindo closes up 2% on approvals for Rizatriptan

Healthcare firm Aurobindo Pharma rose 2.11 percent to close at Rs 193.30 on the Bombay Stock Exchange on Tuesday as the company has received final approval from the US Food & Drug Administration to manufacture and market Rizatriptan Benzoate Tablets.

Post Your Comments

Share Cancel

Healthcare firm Aurobindo Pharma rose 2.11 percent to close at Rs 193.30 on the Bombay Stock Exchange on Tuesday as the company has received final approval from the US Food & Drug Administration to manufacture and market Rizatriptan Benzoate Tablets.

The company said the product was ready for launch. "Rizatriptan Benzoate Tablets 5mg (base) and 10mg (base) is the generic equivalent of Merck and company's Maxalt tablets and is indicated for the acute treatment of migraine with or without aura in adults and pediatric patients 6 to 17 years old," Aurobindo said in a release.

The annual sale of product is approximately USD 300 million for 12 months ending March 2012, according to IMS. The product has been approved out of Unit VII (SEZ) formulations facility in Hyderabad.

Aurobindo has a total of 171 ANDA approvals from USFDA.

Also Read
M&M Dec auto sales up 6% to 45,297 units
Etihad board to consider investment in Kingfisher, Jet

Aurobindo Pharm stock price

On June 24, 2016, Aurobindo Pharma closed at Rs 700.25, down Rs 26.05, or 3.59 percent. The 52-week high of the share was Rs 891.50 and the 52-week low was Rs 582.00.


The company's trailing 12-month (TTM) EPS was at Rs 27.68 per share as per the quarter ended March 2016. The stock's price-to-earnings (P/E) ratio was 25.3. The latest book value of the company is Rs 94.48 per share. At current value, the price-to-book value of the company is 7.41.

Ads by Google

Buy, Hold, Sell ? Hear it first on M3
Aurobindo closes up 2% on approvals for Rizatriptan

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login